Selected research
Industry Research
Radiopharmaceutical CDMO Industry Research Report 2026
Market perspective
The global Radiopharmaceutical CDMO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Radiopharmaceutical CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Radiopharmaceutical CDMO market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Radiopharmaceutical CDMO market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Radiopharmaceutical CDMO include Almac, AtomVie, Cardinal Health, Cyclotek, Eckert & Ziegler, Seibersdorf Labor GmbH, Evergreen Theragnostics, Lantheus and Medi-Radiopharma, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Radiopharmaceutical CDMO market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Radiopharmaceutical CDMO.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Radiopharmaceutical CDMO Market by Company
Almac
AtomVie
Cardinal Health
Cyclotek
Eckert & Ziegler
Seibersdorf Labor GmbH
Evergreen Theragnostics
Lantheus
Medi-Radiopharma
Minerva Imaging
NorthStar
ROTOP Pharmaka GmbH
Nucleus RadioPharma
PharmaLogic
Radiopharmaceutical CDMO Segment by Type
R&D CDMO
Production CDMO
Radiopharmaceutical CDMO Segment by Application
Diagnosis
Treatment
Radiopharmaceutical CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceutical CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceutical CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceutical CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Radiopharmaceutical CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- R&D CDMO
- Production CDMO
Applications
- Diagnosis
- Treatment
Companies covered
- Almac
- AtomVie
- Cardinal Health
- Cyclotek
- Eckert & Ziegler
- Seibersdorf Labor GmbH
- Evergreen Theragnostics
- Lantheus
- Medi-Radiopharma
- Minerva Imaging
- NorthStar
- ROTOP Pharmaka GmbH
- Nucleus RadioPharma
- PharmaLogic
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Radiopharmaceutical CDMO by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 R&D CDMO
- 2.2.3 Production CDMO
- 2.3 Radiopharmaceutical CDMO by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Diagnosis
- 2.3.3 Treatment
- 2.4 Assumptions and Limitations
3 Radiopharmaceutical CDMO Breakdown Data by Type
- 3.1 Global Radiopharmaceutical CDMO Historic Market Size by Type (2021-2026)
- 3.2 Global Radiopharmaceutical CDMO Forecasted Market Size by Type (2027-2032)
4 Radiopharmaceutical CDMO Breakdown Data by Application
- 4.1 Global Radiopharmaceutical CDMO Historic Market Size by Application (2021-2026)
- 4.2 Global Radiopharmaceutical CDMO Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Radiopharmaceutical CDMO Market Perspective (2021-2032)
- 5.2 Global Radiopharmaceutical CDMO Growth Trends by Region
- 5.2.1 Global Radiopharmaceutical CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Radiopharmaceutical CDMO Historic Market Size by Region (2021-2026)
- 5.2.3 Radiopharmaceutical CDMO Forecasted Market Size by Region (2027-2032)
- 5.3 Radiopharmaceutical CDMO Market Dynamics
- 5.3.1 Radiopharmaceutical CDMO Industry Trends
- 5.3.2 Radiopharmaceutical CDMO Market Drivers
- 5.3.3 Radiopharmaceutical CDMO Market Challenges
- 5.3.4 Radiopharmaceutical CDMO Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Radiopharmaceutical CDMO Players by Revenue
- 6.1.1 Global Top Radiopharmaceutical CDMO Players by Revenue (2021-2026)
- 6.1.2 Global Radiopharmaceutical CDMO Revenue Market Share by Players (2021-2026)
- 6.2 Global Radiopharmaceutical CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Radiopharmaceutical CDMO Head Office and Area Served
- 6.4 Global Radiopharmaceutical CDMO Players, Product Type & Application
- 6.5 Global Radiopharmaceutical CDMO Manufacturers Established Date
- 6.6 Global Radiopharmaceutical CDMO Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Radiopharmaceutical CDMO Market Size (2021-2032)
- 7.2 North America Radiopharmaceutical CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Radiopharmaceutical CDMO Market Size by Country (2021-2026)
- 7.4 North America Radiopharmaceutical CDMO Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Radiopharmaceutical CDMO Market Size (2021-2032)
- 8.2 Europe Radiopharmaceutical CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Radiopharmaceutical CDMO Market Size by Country (2021-2026)
- 8.4 Europe Radiopharmaceutical CDMO Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Radiopharmaceutical CDMO Market Size (2021-2032)
- 9.2 Asia-Pacific Radiopharmaceutical CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Radiopharmaceutical CDMO Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Radiopharmaceutical CDMO Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Radiopharmaceutical CDMO Market Size (2021-2032)
- 10.2 South America Radiopharmaceutical CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Radiopharmaceutical CDMO Market Size by Country (2021-2026)
- 10.4 South America Radiopharmaceutical CDMO Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Radiopharmaceutical CDMO Market Size (2021-2032)
- 11.2 Middle East & Africa Radiopharmaceutical CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Radiopharmaceutical CDMO Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Radiopharmaceutical CDMO Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Almac
- 12.1.1 Almac Company Information
- 12.1.2 Almac Business Overview
- 12.1.3 Almac Revenue in Radiopharmaceutical CDMO Business (2021-2026)
- 12.1.4 Almac Radiopharmaceutical CDMO Product Portfolio
- 12.1.5 Almac Recent Developments
- 12.2 AtomVie
- 12.2.1 AtomVie Company Information
- 12.2.2 AtomVie Business Overview
- 12.2.3 AtomVie Revenue in Radiopharmaceutical CDMO Business (2021-2026)
- 12.2.4 AtomVie Radiopharmaceutical CDMO Product Portfolio
- 12.2.5 AtomVie Recent Developments
- 12.3 Cardinal Health
- 12.3.1 Cardinal Health Company Information
- 12.3.2 Cardinal Health Business Overview
- 12.3.3 Cardinal Health Revenue in Radiopharmaceutical CDMO Business (2021-2026)
- 12.3.4 Cardinal Health Radiopharmaceutical CDMO Product Portfolio
- 12.3.5 Cardinal Health Recent Developments
- 12.4 Cyclotek
- 12.4.1 Cyclotek Company Information
- 12.4.2 Cyclotek Business Overview
- 12.4.3 Cyclotek Revenue in Radiopharmaceutical CDMO Business (2021-2026)
- 12.4.4 Cyclotek Radiopharmaceutical CDMO Product Portfolio
- 12.4.5 Cyclotek Recent Developments
- 12.5 Eckert & Ziegler
- 12.5.1 Eckert & Ziegler Company Information
- 12.5.2 Eckert & Ziegler Business Overview
- 12.5.3 Eckert & Ziegler Revenue in Radiopharmaceutical CDMO Business (2021-2026)
- 12.5.4 Eckert & Ziegler Radiopharmaceutical CDMO Product Portfolio
- 12.5.5 Eckert & Ziegler Recent Developments
- 12.6 Seibersdorf Labor GmbH
- 12.6.1 Seibersdorf Labor GmbH Company Information
- 12.6.2 Seibersdorf Labor GmbH Business Overview
- 12.6.3 Seibersdorf Labor GmbH Revenue in Radiopharmaceutical CDMO Business (2021-2026)
- 12.6.4 Seibersdorf Labor GmbH Radiopharmaceutical CDMO Product Portfolio
- 12.6.5 Seibersdorf Labor GmbH Recent Developments
- 12.7 Evergreen Theragnostics
- 12.7.1 Evergreen Theragnostics Company Information
- 12.7.2 Evergreen Theragnostics Business Overview
- 12.7.3 Evergreen Theragnostics Revenue in Radiopharmaceutical CDMO Business (2021-2026)
- 12.7.4 Evergreen Theragnostics Radiopharmaceutical CDMO Product Portfolio
- 12.7.5 Evergreen Theragnostics Recent Developments
- 12.8 Lantheus
- 12.8.1 Lantheus Company Information
- 12.8.2 Lantheus Business Overview
- 12.8.3 Lantheus Revenue in Radiopharmaceutical CDMO Business (2021-2026)
- 12.8.4 Lantheus Radiopharmaceutical CDMO Product Portfolio
- 12.8.5 Lantheus Recent Developments
- 12.9 Medi-Radiopharma
- 12.9.1 Medi-Radiopharma Company Information
- 12.9.2 Medi-Radiopharma Business Overview
- 12.9.3 Medi-Radiopharma Revenue in Radiopharmaceutical CDMO Business (2021-2026)
- 12.9.4 Medi-Radiopharma Radiopharmaceutical CDMO Product Portfolio
- 12.9.5 Medi-Radiopharma Recent Developments
- 12.10 Minerva Imaging
- 12.10.1 Minerva Imaging Company Information
- 12.10.2 Minerva Imaging Business Overview
- 12.10.3 Minerva Imaging Revenue in Radiopharmaceutical CDMO Business (2021-2026)
- 12.10.4 Minerva Imaging Radiopharmaceutical CDMO Product Portfolio
- 12.10.5 Minerva Imaging Recent Developments
- 12.11 NorthStar
- 12.11.1 NorthStar Company Information
- 12.11.2 NorthStar Business Overview
- 12.11.3 NorthStar Revenue in Radiopharmaceutical CDMO Business (2021-2026)
- 12.11.4 NorthStar Radiopharmaceutical CDMO Product Portfolio
- 12.11.5 NorthStar Recent Developments
- 12.12 ROTOP Pharmaka GmbH
- 12.12.1 ROTOP Pharmaka GmbH Company Information
- 12.12.2 ROTOP Pharmaka GmbH Business Overview
- 12.12.3 ROTOP Pharmaka GmbH Revenue in Radiopharmaceutical CDMO Business (2021-2026)
- 12.12.4 ROTOP Pharmaka GmbH Radiopharmaceutical CDMO Product Portfolio
- 12.12.5 ROTOP Pharmaka GmbH Recent Developments
- 12.13 Nucleus RadioPharma
- 12.13.1 Nucleus RadioPharma Company Information
- 12.13.2 Nucleus RadioPharma Business Overview
- 12.13.3 Nucleus RadioPharma Revenue in Radiopharmaceutical CDMO Business (2021-2026)
- 12.13.4 Nucleus RadioPharma Radiopharmaceutical CDMO Product Portfolio
- 12.13.5 Nucleus RadioPharma Recent Developments
- 12.14 PharmaLogic
- 12.14.1 PharmaLogic Company Information
- 12.14.2 PharmaLogic Business Overview
- 12.14.3 PharmaLogic Revenue in Radiopharmaceutical CDMO Business (2021-2026)
- 12.14.4 PharmaLogic Radiopharmaceutical CDMO Product Portfolio
- 12.14.5 PharmaLogic Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst